Dr. Jinyu Shan stands as a pivotal figure in molecular microbiology, seamlessly integrating an illustrious academic career with significant contributions to industry innovation. Fluent in English and Mandarin Chinese, and proficient in Cantonese, Dr. Shan leverages his linguistic capabilities to foster international collaborations and effectively communicate complex scientific concepts. Holding advanced degrees from renowned institutions like Shandong University, Nankai University, and the University of Warwick, Dr. Shan's extensive educational background lays the foundation for his groundbreaking work in both academia and biotechnology. His efforts are particularly notable in the fields of phage therapy and molecular diagnostics for bacterial infections such as Lyme and tick-borne diseases, where he combines research excellence with practical application and citizen sciences to address pressing public health needs. At the University of Leicester and Phelix Research & Development, Dr. Shan has led pioneering research in phage-based diagnostics and therapies and directed the development and commercialization (IP licencing) of innovative diagnostic kits, adhering to strict ISO standards. His leadership roles at Youseq Ltd, Marker Diagnostics Ltd and Rosalind Franklin Laboratory have further showcased his expertise in developing biomarkers and managing laboratory operations to meet ISO15189 standards. Dr. Shan's scholarly output includes influential publications on novel diagnostic methods and active engagement in public health through citizen science projects and popular science articles, establishing him as a leader in his field. He is a sought-after speaker at international microbiology and infectious disease conferences, reflecting his commitment to scientific education and mentoring. Dr. Shan is actively involved with professional societies and has served as a judge for the LymeX Diagnostics Prize Competition, highlighting his dedication to advancing Lyme disease diagnostics. His interdisciplinary approach exemplifies his commitment to improving public health through innovative biomedical research. Recently, Dr. Shan's work has gained additional acclaim as he joined the BBSRC ICURe Programme, aimed at commercializing his phage-based Lyme diagnostic technologies. This recognition underscores the impact and commercial potential of his research, bridging the gap between laboratory discoveries and clinical application, thus advancing patient care globally. This achievement marks a significant milestone in Dr. Shan's career, emphasizing his influence as a driving force in the evolution of infectious disease diagnostics.